We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+12.85%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$16.7M
Cap. Flow
-$5.1M
Cap. Flow %
-1.78%
Top 10 Hldgs %
46.84%
Holding
97
New
24
Increased
16
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$16.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
ESTA icon
Establishment Labs
ESTA
+$6.8M
5
KURA icon
Kura Oncology
KURA
+$6.54M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$16.8M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
3
MRK icon
Merck
MRK
+$12.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.75M
5
BLU
BELLUS Health Inc.
BLU
+$6.35M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
51
DELISTED
Apellis Pharmaceuticals
APLS
$911K 0.32%
10,000
-25,000
-71% -$2.16M
AXSM icon
52
Axsome Therapeutics
AXSM
$11.7B
$898K 0.31%
+12,500
New +$922K
MIST icon
53
Milestone Pharmaceuticals
MIST
$147M
$855K 0.3%
300,068
+100,686
+50% +$380K
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$7.11B
$776K 0.27%
30,000
-65,000
-68% -$1.73M
PBYI icon
55
Puma Biotechnology
PBYI
$420M
$714K 0.25%
202,349
+25,000
+14% +$78K
PCVX icon
56
Vaxcyte
PCVX
$8.02B
$695K 0.24%
13,923
-48,300
-78% -$2.29M
JSPR icon
57
Jasper Therapeutics
JSPR
$27.6M
$653K 0.23%
47,695
– –
IMTXW
58
DELISTED
Immatics N.V. Warrants
IMTXW
$633K 0.22%
187,204
– –
TRML
59
DELISTED
Tourmaline Bio
TRML
$608K 0.21%
+20,000
New +$511K
BBIO icon
60
BridgeBio Pharma
BBIO
$15.9B
$604K 0.21%
35,133
-284,867
-89% -$4.29M
VIR icon
61
Vir Biotechnology
VIR
$1.57B
$491K 0.17%
+20,000
New +$502K
NUVB icon
62
Nuvation Bio
NUVB
$2.19B
$450K 0.16%
250,000
– –
NCEL
63
NewcelX Ltd
NCEL
$20.7M
$440K 0.15%
1,000
+140
+16% +$67.4K
CNTX icon
64
Context Therapeutics
CNTX
$56M
$428K 0.15%
+267,574
New +$228K
NAMSW icon
65
NewAmsterdam Pharma Warrant
NAMSW
$87.5M
$77.3K 0.03%
37,000
– –
ARAV
66
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$42.3K 0.01%
+33,600
New +$54.5K
RCKTW icon
67
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$13.9K ﹤0.01%
75,000
– –
ACRS icon
68
CALL
Aclaris Therapeutics
ACRS
$786M
– –
-129,100
Closed -$1.04M
ARGX icon
69
argenx
ARGX
$53.9B
– –
-10,750
Closed -$4.01M
AZN icon
70
CALL
AstraZeneca
AZN
$258B
– –
-25,000
Closed -$3.47M
BMRN icon
71
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-25,000
Closed -$2.43M
COGT icon
72
Cogent Biosciences
COGT
$6.61B
– –
-143,064
Closed -$1.54M
ESPR
73
PUT
DELISTED
Esperion Therapeutics
ESPR
– –
-350,000
Closed -$557K
ETNB
74
CALL
DELISTED
89bio
ETNB
– –
-36,200
Closed -$551K
ETNB
75
DELISTED
89bio
ETNB
– –
-200,000
Closed -$3.05M
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Affinity Asset Advisors held 97 positions worth $286M, down 5.5% from $303M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors's Q2 2023 filing shows 24 new, 16 increased, 16 reduced and 27 closed positions. Its largest new stake was Kyntra Bio: 39,332 shares worth $2.65M. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier.

  • Affinity Asset Advisors's largest Q2 2023 buy was Kyntra Bio: 39,332 shares worth $2.65M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2023, an estimated $6.8M increase.
  • Affinity Asset Advisors's biggest Q2 2023 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $16.8M.
  • Affinity Asset Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $286M portfolio in Q2 2023.
  • Affinity Asset Advisors opened 24 new positions and closed 27 in Q2 2023.
  • Affinity Asset Advisors's portfolio value fell 5.5% quarter-over-quarter to $286M.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.